Literature DB >> 16464794

Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience.

Liv Hege Aksnes1, Kirsten Sundby Hall, Gunnar Folleraas, Anna Elisabeth Stenwig, Bodil Bjerkehagen, Ingeborg Taksdal, Mette Winderen, Oyvind Sverre Bruland, Gunnar Saeter.   

Abstract

All cases of high-grade osteosarcoma (OS) (n = 196) and Ewing's sarcoma of bone (ES) (n = 56) treated at the Norwegian Radium Hospital in the period 1980-1999 were analyzed retrospectively. They were allocated to consecutive ten-year periods by their time of diagnosis. Patient and tumour characteristics have been relatively stable. Eighty percent of all patients received surgical treatment and the amputation rate decreased from 64% to 23%. The percentage of patients receiving chemotherapy has remained around 80%. The use of radiotherapy in primary treatment decreased gradually from 33% to 18%. Sarcoma specific survival (SSS) at five years for all patients increased significantly from 39% to 53%. Similar trends for improvement were seen for both OS and ES. In multivariate analysis, independent prognostic factors for improved SSS were non-metastatic disease at diagnosis, age under 40, extremity tumours, small tumours and treatment from 1995 onwards. No major new treatment options have emerged over these 20 years. The improved outcome appears partly to be due to refinements in the use of existing modalities and improved quality and integration of multidisciplinary approaches. Improved formalized organisation of the sarcoma group and annual audited reports of its patient and research activity may also have contributed to improved focus and performance.

Entities:  

Mesh:

Year:  2006        PMID: 16464794     DOI: 10.1080/02841860500466624

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  12 in total

1.  Impact of family structure on long-term survivors of osteosarcoma.

Authors:  A Bressoud; O Real del Sarte; S Stiefel; P Mordasini; L Perey; J Bauer; P F Leyvraz; S Leyvraz
Journal:  Support Care Cancer       Date:  2007-01-05       Impact factor: 3.603

2.  Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.

Authors:  S Jabeen; L Holmboe; G I G Alnæs; A M Andersen; K S Hall; V N Kristensen
Journal:  Pharmacogenomics J       Date:  2015-03-17       Impact factor: 3.550

Review 3.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

4.  GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.

Authors:  Monrat Chulanetra; Atthapan Morchang; Elias Sayour; Lamis Eldjerou; Rowan Milner; Joanne Lagmay; Matt Cascio; Brian Stover; William Slayton; Wanpen Chaicumpa; Pa-Thai Yenchitsomanus; Lung-Ji Chang
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

5.  Young survivors of malignant bone tumours in the extremities: a comparative study of quality of life, fatigue and mental distress.

Authors:  Liv Hege Aksnes; Kirsten Sundby Hall; Nina Jebsen; Sophie D Fosså; Alv A Dahl
Journal:  Support Care Cancer       Date:  2007-03-09       Impact factor: 3.603

6.  Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Authors:  Stine H Kresse; Halfdan Rydbeck; Magne Skårn; Heidi M Namløs; Ana H Barragan-Polania; Anne-Marie Cleton-Jansen; Massimo Serra; Knut Liestøl; Pancras C W Hogendoorn; Eivind Hovig; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

7.  Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern.

Authors:  Heidi M Namløs; Stine H Kresse; Christoph R Müller; Jørn Henriksen; Rita Holdhus; Gunnar Sæter; Oyvind S Bruland; Bodil Bjerkehagen; Vidar M Steen; Ola Myklebost
Journal:  Sarcoma       Date:  2012-02-28

8.  Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival?

Authors:  B Bjerkehagen; M C Småstuen; K S Hall; S Skjeldal; S Smeland; S D Fosså
Journal:  Br J Cancer       Date:  2011-12-15       Impact factor: 7.640

9.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

Authors:  Annmeik M van Maldegem; Pancras Cw Hogendoorn; Andrew B Hassan
Journal:  Clin Sarcoma Res       Date:  2012-02-08

10.  A systematic review of the recent quality of life studies in adult extremity sarcoma survivors.

Authors:  Melissa H Tang; Donald J W Pan; David J Castle; Peter F M Choong
Journal:  Sarcoma       Date:  2012-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.